A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
Study Details
Study Description
Brief Summary
The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: LY3875383 (Part A) Single-ascending doses of LY3875383 administered subcutaneously (SC). |
Drug: LY3875383
Administered SC.
|
| Experimental: LY3875383 (Part B) Single doses of LY3875383 administered SC. |
Drug: LY3875383
Administered SC.
|
| Experimental: LY3875383 (Part C) Single doses of LY3875383 administered SC. |
Drug: LY3875383
Administered SC.
|
| Experimental: LY3875383 (Part D) Single doses of LY3875383 administered SC. |
Drug: LY3875383
Administered SC.
|
| Placebo Comparator: Placebo (Part A) Placebo administered SC. |
Drug: Placebo
Administered SC.
|
| Placebo Comparator: Placebo (Part B) Placebo administered SC. |
Drug: Placebo
Administered SC.
|
| Placebo Comparator: Placebo (Part C) Placebo administered SC. |
Drug: Placebo
Administered SC.
|
| Placebo Comparator: Placebo (Part D) Placebo administered SC. |
Drug: Placebo
Administered SC.
|
Outcome Measures
Primary Outcome Measures
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 53]
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
Secondary Outcome Measures
- Pharmacokinetics (PK):Area Under the Concentration Versus Time Curve (AUC) of LY3875383 [Predose up to 72 hours post dose]
PK: AUC of LY3875383
- PK: Maximum Observed Concentration (Cmax) of LY3875383 [Predose up to 72 hours post dose]
PK: Cmax of LY3875383
- Part C and D only: Pharmacodynamics (PD): Percentage Change from Baseline in Fasting Triglyceride (TG) [Baseline through up to Week 53]
Part C and D only: PD: Percentage Change from Baseline in Fasting TG
- Part D only: PD: Percentage Change from Baseline in Fasting Non-High-Density Lipoprotein Cholesterol (HDL-C) [Baseline through Week 53]
Part D only: PD: Percentage Change from Baseline in Fasting non-HDL-C
Eligibility Criteria
Criteria
Inclusion Criteria:
All participants:
-
Have a body mass index (BMI) between 18.5 and 40 kilograms per square meter (kg/m²), inclusive.
-
Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP).
Healthy participants (Part A):
• Participants must be overtly healthy, as determined by medical evaluation.
For Part B:
• Participants must be first-generation Japanese, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
Hypertriglyceridemia participants (Parts C and D):
For Part C:
-
Have history of very high triglyceride (lipid) level 500 mg/dL ≤ TG <2000 mg/dL, which needs to be further confirmed at screening.
-
Participants must be on a lipid-modifying diet and can be on stable lipid-lowering drugs (LLDs) for at least 8 weeks before screening and plan to continue the same throughout the study duration.
For Part D:
-
Have history of high triglyceride (lipid) level between 150 mg/dL and 500 mg/dL inclusive at pre-screening or based on medical history and confirmed at screening and Low-density lipoprotein cholesterol (LDL-C) level of ≥40 mg/dL.
-
Participants must be on a stable moderate or high-intensity dose of a statin for at least 8 weeks before screening and plan to continue the same medication and dose throughout the study duration.
Exclusion Criteria:
All participants:
-
Participants must not be currently participating in or completed a clinical trial within the last 30 days
-
Have donated blood of more than 500 mL within the previous 3 months
-
Have one of the following viral infections: hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV).
-
Participants must not be heavy alcohol drinkers or cigarette smokers.
For Part C: Have active pancreatitis within the last 6 months
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | ProSciento, Inc | Chula Vista | California | United States | 91911 |
| 2 | Altasciences Clinical Los Angeles, Inc | Cypress | California | United States | 90630 |
| 3 | Qps-Mra, Llc | Miami | Florida | United States | 33143 |
| 4 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
| 5 | Endeavor Clinical Trials | San Antonio | Texas | United States | 78240 |
| 6 | Lilly Centre for Clinical Pharmacology | Singapore | Singapore | 138623 |
Sponsors and Collaborators
- Eli Lilly and Company
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 18537
- J4D-MC-EZFA